Beone Medicines Ltd share price logo

Beone Medicines Ltd Share Price

NASDAQ: ONC

Mid Cap

$332.33

+8.00

(+2.47%)

as on

Beone Medicines Ltd Stock Performance

as on September 16, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $330
    $334.02
    downward going graph

    0.70%

    Downside

    0.51%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $172.67
    $351.27
    downward going graph

    48.04%

    Downside

    5.70%

    Upside

    downward going graph

Beone Medicines Ltd share price movements today

Previous Close
$324.34
Open
$332.24
Volume
304.4K
Day's Low - High
$330 - $334.02
52 Week Low - High
$172.67 - $351.27

Beone Medicines Ltd Historical Returns

1 Month Return
+ 0.93 %
3 Month Return
+ 20.29 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Beone Medicines Ltd Stock Fundamentals & Key Indicators

Check Beone Medicines Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$38.7B

EPS (TTM)

3.3355

Dividend Yield

0.00%

PE Ratio (TTM)

0

P/B Ratio

0

PEG Ratio

0

Return On Equity TTM

36843700.00%

Beone Medicines Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Beone Medicines Ltd with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
NA$38.7BNANA-3.89%
BUY$61.1B256.98%-505.15-12.96%
BUY$101.1B47.85%28.0731.86%
BUY$59.4B-3.43%14.1131.37%

Beone Medicines Ltd Stock's Interest Amongst Investors

Search interest for Beone Medicines Ltd Stock has decreased by -48% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-48% versus previous 30 day period

Beone Medicines Ltd Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
447
595
781
634
751
929
1,001
1,127
1,117
1,315
Gross Profit
-42
76
684
528
626
791
831
967
952
1,150
Operating Income
-371
-318
-133
-383
-261
-107
-120
-79
11
87
EBITDA
-351
-296
-112
-359
-236
-83
-48
-29
43
123
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
21
23
25
24
71
50
32
35
Income Before Tax
-336
-367
229
-350
-243
-105
-98
-85
20
99
Income Tax Expense
11
13
13
121
7
14
23
66
19
5
Net Income
-348
-381
215
-2,656
-251
-120
-121
-151
1
94
Net Profit Margin
-77.81%
-64.03%
27.57%
-418.80%
-33.41%
-12.96%
-12.12%
-13.47%
0.11%
7.17%

Beone Medicines Ltd Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
8
1
238
198
428
308
1,176
1,415
2,458
3,810
Gross Profit
-49
-96
-35
-509
-570
-1,056
-447
-511
2,078
3,216
Operating Income
-56
-117
-98
-705
-959
-1,657
-1,438
-1,789
-1,207
-568
EBITDA
-55
-115
-93
-695
-941
-1,625
-1,392
-1,723
-1,120
-396
Interest Expense
1
0
-
13
-
-
-
52
-
-
Depreciation
-
-
-
-
-
31
46
66
87
171
Income Before Tax
-57
-119
-91
-689
-943
-1,618
-1,438
-1,961
-825
-533
Income Tax Expense
-2
0
2
-15
6
-17
-25
42
55
111
Net Income
-57
-119
-93
-673
-950
-1,600
-1,413
-2,003
-881
-644
Net Profit Margin
-647.71%
-11141.78%
-39.06%
-339.91%
-221.99%
-518.18%
-120.15%
-141.52%
-35.86%
-16.92%

Beone Medicines Ltd Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-381
215
-367
-251
-120
-121
-151
1
94
Operating Cash Flow
-293
-78
-221
-308
-95
188
75
44
263
Investing Cash Flow
67
-186
-62
-209
-111
-133
-93
-121
-66
Financing Cash Flow
166
-76
347
162
23
12
-4
-33
35
Change in Cash
-122
-340
105
-378
-189
95
-74
-108
255

Beone Medicines Ltd Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-119
-93
-674
-950
-1,600
-1,413
-2,003
-881
-644
Operating Cash Flow
-89
12
-547
-750
-1,283
-1,298
-1,496
-1,157
-140
Investing Cash Flow
-221
-356
-637
554
-3,168
640
1,077
60
-548
Financing Cash Flow
380
490
1,690
85
5,202
3,636
-18
416
193
Change in Cash
69
152
501
-119
769
2,992
-507
-689
-547

Insights on Beone Medicines Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Beone Medicines Ltd has shown a strong improvement in its net profit over the last three quarters. The net profit increased from -151.88 million dollars to 94.32 million dollars, marking a significant turnaround. On average, the company has experienced a remarkable increase of about 6078.9% in net profit each quarter.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Beone Medicines Ltd has shown positive revenue growth over the last two quarters. The company's revenue increased from $1.11 billion to $1.31 billion, reflecting an average increase of 15.1% per quarter.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 118.7% return, outperforming this stock by 12.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 72.3% return, outperforming this stock by 7.2%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, ONC stock has moved down by -7.6%

About Beone Medicines Ltd

BeOne Medicines Ltd., formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
OrganisationBeone Medicines Ltd
HeadquartersAeschengraben 27, Basel, Switzerland, 4051
CEOMr. John V. Oyler
E-voting on sharesClick here to vote

Key Management of Beone Medicines Ltd

Name

Title

Mr. Marcello Damiani

Chief Technology Officer

Ms. Eleanor Duff Ph.D.

Senior VP & Head of Corporate Communications

Mr. John V. Oyler

Co-Founder, Executive Chairman & CEO

Mr. Aaron Rosenberg

Chief Financial Officer

Mr. Wang Lai Ph.D.

Global Head of Research & Development

Mr. Titus B. Ball

VP & Chief Accounting Officer

Ms. Liza Heapes

Head of Investor Relations

Dr. Xiaobin Wu Ph.D.

President, COO & GM of China

Dr. Xiaodong Wang Ph.D.

Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder

Mr. Chan Lee

General Counsel & Senior VP

FAQs

What is Beone Medicines Ltd share price today?

Beone Medicines Ltd share price today is $332.33 as on at the close of the market. Beone Medicines Ltd share today touched a day high of $334.02 and a low of $330.

What is the 52 week high and 52 week low for Beone Medicines Ltd share?

Beone Medicines Ltd share touched a 52 week high of $351.27 on and a 52 week low of $172.67 on . Beone Medicines Ltd stock price today i.e. is closed at $332.33,which is 5.39% down from its 52 week high and 92.47% up from its 52 week low.

What is Beone Medicines Ltd's market capitalisation today?

Beone Medicines Ltd market capitalisation is $0.04T as on .

How to invest in Beone Medicines Ltd Stock (ONC) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Beone Medicines Ltd on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Beone Medicines Ltd Shares that will get you 0.0045 shares as per Beone Medicines Ltd share price of $332.33 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy Beone Medicines Ltd Stock (ONC) from India?

Indian investors can start investing in Beone Medicines Ltd (ONC) shares with as little as ₹88.141 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Beone Medicines Ltd stock (as per the Rupee-Dollar exchange rate as on ). Based on Beone Medicines Ltd share’s latest price of $332.33 as on September 16, 2025 at 1:29 am IST, you will get 0.0301 shares of Beone Medicines Ltd. Learn more about fractional shares .